WO2002079203A8 - Composes a action pharmaceutique - Google Patents

Composes a action pharmaceutique

Info

Publication number
WO2002079203A8
WO2002079203A8 PCT/IB2002/000854 IB0200854W WO02079203A8 WO 2002079203 A8 WO2002079203 A8 WO 2002079203A8 IB 0200854 W IB0200854 W IB 0200854W WO 02079203 A8 WO02079203 A8 WO 02079203A8
Authority
WO
WIPO (PCT)
Prior art keywords
pde
imidazo
inhibitors
triazine derivatives
curative
Prior art date
Application number
PCT/IB2002/000854
Other languages
English (en)
Other versions
WO2002079203A1 (fr
Inventor
Charlotte Moira Norfo Allerton
Kevin Neil Dack
Mark Ian Kemp
Original Assignee
Pfizer Ltd
Charlotte Moira Norfo Allerton
Kevin Neil Dack
Mark Ian Kemp
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd, Charlotte Moira Norfo Allerton, Kevin Neil Dack, Mark Ian Kemp, Pfizer filed Critical Pfizer Ltd
Priority to MXPA03005990A priority Critical patent/MXPA03005990A/es
Priority to CA002442329A priority patent/CA2442329A1/fr
Priority to BR0208463-5A priority patent/BR0208463A/pt
Priority to AU2002241211A priority patent/AU2002241211A1/en
Priority to EP02707056A priority patent/EP1395589A1/fr
Priority to JP2002577827A priority patent/JP2004528320A/ja
Publication of WO2002079203A1 publication Critical patent/WO2002079203A1/fr
Publication of WO2002079203A8 publication Critical patent/WO2002079203A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention concerne des composés représentés par la formule générale (1) dans laquelle R?1, R2, R3, R4¿, X, Y et A sont comme définis dans le descriptif. Ces composés conviennent bien pour le traitement curatif et prophylactique d'un état pathologique pour lequel il est souhaitable d'inhiber une phosphodiestérase de guanosine 3', 5' monophosphatée cyclique (telle que cGMP PDE5).
PCT/IB2002/000854 2001-03-28 2002-03-19 Composes a action pharmaceutique WO2002079203A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA03005990A MXPA03005990A (es) 2001-03-28 2002-03-19 Compuestos farmaceuticalmente activos.
CA002442329A CA2442329A1 (fr) 2001-03-28 2002-03-19 Composes a action pharmaceutique
BR0208463-5A BR0208463A (pt) 2001-03-28 2002-03-19 Compostos farmaceuticamente ativos
AU2002241211A AU2002241211A1 (en) 2001-03-28 2002-03-19 Imidazo-triazine derivatives as pde 5 inhibitors
EP02707056A EP1395589A1 (fr) 2001-03-28 2002-03-19 Derives d'imidazotriazine en tant qu'inhibiteurs de pde 5
JP2002577827A JP2004528320A (ja) 2001-03-28 2002-03-19 医薬活性化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0107751.0A GB0107751D0 (en) 2001-03-28 2001-03-28 Pharmaceutically active compounds
GB0107751.0 2001-03-28

Publications (2)

Publication Number Publication Date
WO2002079203A1 WO2002079203A1 (fr) 2002-10-10
WO2002079203A8 true WO2002079203A8 (fr) 2002-11-21

Family

ID=9911744

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/000854 WO2002079203A1 (fr) 2001-03-28 2002-03-19 Composes a action pharmaceutique

Country Status (8)

Country Link
EP (1) EP1395589A1 (fr)
JP (1) JP2004528320A (fr)
AU (1) AU2002241211A1 (fr)
BR (1) BR0208463A (fr)
CA (1) CA2442329A1 (fr)
GB (1) GB0107751D0 (fr)
MX (1) MXPA03005990A (fr)
WO (1) WO2002079203A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2462200A1 (fr) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetiques de metallopeptides biologiquement actifs
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
ES2284081T3 (es) * 2003-12-19 2007-11-01 Bristol-Myers Squibb Company Heterociclos azabiciclicos como modulares de receptores canabinoides.
TW200530246A (en) * 2003-12-19 2005-09-16 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
WO2008021781A1 (fr) 2006-08-07 2008-02-21 Incyte Corporation Utilisation de triazolotriazines en tant qu'inhibiteurs des kinases
ES2689444T3 (es) 2006-11-22 2018-11-14 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
SI2300455T1 (sl) 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
BR112012019302B1 (pt) 2010-02-03 2022-06-21 Incyte Holdings Corporation Imidazo[1,2-b] [1,2,4]triazinas como inibidores de c-met, composição que as compreende e métodos in vitro de inibir a atividade de c-met cinase, de inibir a via de sinalização da hgf/c-met cinase em uma célula e de inibir a atividade proliferativa de uma célula
CN102382129B (zh) * 2010-08-19 2014-02-26 山东轩竹医药科技有限公司 螺环取代的磷酸二酯酶抑制剂
CN102372730B (zh) * 2010-08-19 2014-03-26 山东轩竹医药科技有限公司 桥环取代的磷酸二酯酶抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
SK287161B6 (sk) * 1997-11-12 2010-02-08 Bayer Healthcare Ag 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie
CA2323008C (fr) * 1999-10-11 2005-07-12 Pfizer Inc. Composes pharmaceutiques actifs
DE10010067A1 (de) * 2000-03-02 2001-09-06 Bayer Ag Neue Imidazotriazinone und ihre Verwendung

Also Published As

Publication number Publication date
AU2002241211A1 (en) 2002-10-15
CA2442329A1 (fr) 2002-10-10
EP1395589A1 (fr) 2004-03-10
WO2002079203A1 (fr) 2002-10-10
BR0208463A (pt) 2004-03-02
MXPA03005990A (es) 2005-02-14
GB0107751D0 (en) 2001-05-16
JP2004528320A (ja) 2004-09-16

Similar Documents

Publication Publication Date Title
AP2002002455A0 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
MXPA03005937A (es) Compuestos farmaceuticamente activos.
MXPA03006310A (es) Compuestos farmaceuticamente activos.
CA2287552A1 (fr) Inhibiteurs de la pde5 specifique de la gmpc a base de pyrazolopyrimidinone pour le traitement de la dysfonction sexuelle
CA2347950A1 (fr) Inhibiteurs de cgmp pde5 de pyrazolopyrimidinone servant a traiter le dysfonctionnement sexuel
CA2322900A1 (fr) Derives de substitution 2-(hetero)aryl purin-6-ones en tant qu'inhibiteurs de la phosphodiesterase
BR0004779A (pt) Compostos farmaceuticamente ativos
GB9823103D0 (en) Pharmaceutically active compounds
WO2002064590A3 (fr) Composes chimiques
WO2001087038A3 (fr) Derives $g(b)-carboline utiles en tant qu'inhibiteurs de la phosphodiesterase
WO2005049581A8 (fr) Derives de pyridazine-3(2h)-ones et utilisation en tant qu'inhibiteurs de pde4
ES2195785A1 (es) Nuevos derivados de piridazin-3(2h)-ona.
WO2002064591A3 (fr) Composes chimiques
WO2003000695A8 (fr) Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases
WO2001019829A3 (fr) Pyrazolopyrimidines en tant qu'agents therapeutiques
WO2002102313A3 (fr) Inhibiteurs pyrimidine de la phosphodiesterase (pde) 7
WO2002000657A3 (fr) Composes chimiques
WO2008070313A3 (fr) Dérivés de 3-(dihydro-1h-pyrazolo [4,3-d]pyrimidin-5-yl)-4-propoxybenzènesulfonamide et procédés d'utilisation
WO2002028865A3 (fr) Composés chimiques
WO2002079203A8 (fr) Composes a action pharmaceutique
WO2000059449A3 (fr) Derives de purine possedant une activite d'inhibition de la phosphodiesterase iv
AP2002002462A0 (en) Pharmaceutically active compounds.
CA2412596A1 (fr) Inhibiteurs de phosphodiesterase specifique de gmp cyclique
EP1241170A3 (fr) Dérivés de pyrazolopyrimidine
WO2002000656A3 (fr) Composes chimiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/005990

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002707056

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002577827

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2442329

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002707056

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002707056

Country of ref document: EP